Ovid Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Ovid Therapeutics Inc. on June 8, 2023. The record date for the meeting was April 13, 2023, with 70,521,340 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders participated in four proposals with the following outcomes:
- Proposal 1 (Election of Directors): All nominees were elected to serve three-year terms. Jeremy M. Levin received the highest support with 44,455,812 votes "For," while Karen Bernstein received 39,704,019 votes "For."
- Proposal 2 (Say-on-Pay): Stockholders approved the compensation of named executive officers on an advisory basis. 44,681,350 votes were cast "For" compared to 113,666 "Against."
- Proposal 3 (Say-on-Pay Frequency): Stockholders recommended an annual frequency for future advisory votes on executive compensation. 44,015,622 votes were cast for "One Year."
- Proposal 4 (Ratification of Auditors): Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. 61,226,349 votes were cast "For."
Guidance, Outlook, and Management Commentary
Based on the voting results and the Board's prior recommendation, the Board determined that future advisory Say-on-Pay votes will be held on an annual basis. This frequency will remain in effect until the next stockholder advisory vote on frequency, which will occur no later than the 2029 annual meeting.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 27, 2023, for detailed descriptions of the director nominees and executive compensation.
- Confirm the quorum status: 61,294,999 shares (86.91%) were present, constituting a valid quorum.
- Review the specific terms of the three-year director terms approved in Proposal 1.
- Check subsequent filings for the official appointment of KPMG LLP following the ratification vote.